According to Zacks, “Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. “
NTRA has been the topic of several other reports. Piper Jaffray Companies set a $40.00 price target on shares of Tapestry and gave the company a buy rating in a report on Monday, June 10th. BidaskClub cut shares of Virtu Financial from a sell rating to a strong sell rating in a report on Wednesday, June 12th. Finally, Canaccord Genuity reaffirmed an average rating on shares of Kellogg in a report on Tuesday, June 25th. Three analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of Buy and an average target price of $30.14.
NTRA opened at $25.64 on Wednesday. The company has a fifty day moving average of $24.89. The company has a debt-to-equity ratio of 20.88, a quick ratio of 1.73 and a current ratio of 1.85. Natera has a 12-month low of $11.08 and a 12-month high of $29.62.
Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, May 9th. The medical research company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.05. The firm had revenue of $66.82 million for the quarter, compared to analysts’ expectations of $66.40 million. Natera had a negative net margin of 49.33% and a negative return on equity of 699.31%. As a group, equities research analysts anticipate that Natera will post -2.17 EPS for the current fiscal year.
In other Natera news, Chairman Matthew Rabinowitz sold 1,418 shares of the business’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $24.79, for a total transaction of $35,152.22. Following the completion of the sale, the chairman now owns 1,286,612 shares in the company, valued at $31,895,111.48. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Jonathan Sheena sold 1,033 shares of the business’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $24.79, for a total transaction of $25,608.07. Following the sale, the insider now owns 240,061 shares of the company’s stock, valued at approximately $5,951,112.19. The disclosure for this sale can be found here. In the last quarter, insiders have sold 5,771 shares of company stock valued at $140,742. 9.29% of the stock is owned by insiders.
A number of hedge funds have recently added to or reduced their stakes in the business. Marshall Wace LLP bought a new stake in Natera during the first quarter valued at $264,000. MYDA Advisors LLC bought a new stake in Natera during the first quarter valued at $722,000. AGF Investments Inc. bought a new stake in Natera during the first quarter valued at $1,031,000. NumerixS Investment Technologies Inc increased its stake in Natera by 86.5% during the first quarter. NumerixS Investment Technologies Inc now owns 13,616 shares of the medical research company’s stock valued at $272,000 after purchasing an additional 6,316 shares during the last quarter. Finally, Asymmetry Capital Management L.P. bought a new stake in Natera during the first quarter valued at $628,000. Hedge funds and other institutional investors own 80.27% of the company’s stock.
Natera Company Profile
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Featured Article: Trade Deficit
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.